Gatifloxacin resistance and mutations in gyrA after unsuccessful Helicobacter pylori eradication in Japan

被引：45
作者：
Nishizawa, T
Suzuki, H
Kurabayasi, K
Masaoka, T
Muraoka, H
Mori, M
Iwasaki, E
Kobayashi, I
Hibi, T
机构：
[1] Keio Univ, Sch Med, Dept Internal Med, Shinjuku Ku, Tokyo 1608582, Japan
[2] Keio Univ, Sch Med, Ctr Integrated Med Res, Tokyo 1608582, Japan
[3] Keio Univ, Sch Med, Dept Emergency Med, Tokyo 1608582, Japan
[4] Kitasato Inst Hosp, Dept Gastroenterol, Tokyo, Japan
[5] Mitsubishi Kagaku Bioclin Labs, Tokyo, Japan
来源：
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2006年 / 50卷 / 04期
关键词：
D O I：
10.1128/AAC.50.4.1538-1540.2006
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
A high resistance rate (47.9%) to gatifloxacin (GAT; 8-methoxy fluoroquinolone) in Helicobacter pylori (H. pylori) strains from 48 Japanese patients is observed after unsuccessful H. pylori eradication. A significant association between MICs for GAT equal to or above 1 mu g/ml and mutations of the gyrA gene of H. pylori was demonstrated.
引用
收藏
页码：1538 / 1540
页数：3
相关论文
共 16 条
[1]  
[Anonymous], PERF STAND ANT SUSC
[2]   Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin [J].
Bauernfeind, A .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 40 (05) :639-651
[3]   The status of antimicrobial resistance of Helicobacter pylori in eastern Europe [J].
Boyanova, L ;
Mentis, A ;
Gubina, M ;
Rozynek, E ;
Gosciniak, G ;
Kalenic, S ;
Göral, V ;
Kupcinskas, L ;
Kantarçeken, B ;
Aydin, A ;
Archimandritis, A ;
Dzierzanowska, D ;
Vcev, A ;
Ivanova, K ;
Marina, M ;
Mitov, I ;
Petrov, P ;
Özden, A ;
Popova, M .
CLINICAL MICROBIOLOGY AND INFECTION, 2002, 8 (07) :388-396
[4]   In vitro activity of fluoroquinolone and the gyrA gene mutation in Helicobacter pylori strains isolated from children [J].
Fujimura, S ;
Kato, S ;
Iinuma, K ;
Watanabe, A .
JOURNAL OF MEDICAL MICROBIOLOGY, 2004, 53 (10) :1019-1022
[5]   Secondary resistance among 554 isolates of Helicobacter pylori after failure of therapy [J].
Heep, M ;
Kist, M ;
Strobel, S ;
Beck, D ;
Lehn, N .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2000, 19 (07) :538-541
[6]   Compound efflux in Helicobacter pylori [J].
Kutschke, A ;
de Jonge, BLM .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (07) :3009-3010
[7]   In vivo selection of Campylobacter isolates with high levels of fluoroquinolone resistance associated with gyrA mutations and the function of the CmeABC efflux pump [J].
Luo, N ;
Sahin, O ;
Lin, J ;
Michel, LO ;
Zhang, QJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (01) :390-394
[8]   Second-line treatment of Helicobacter pylori infection after dilution agar methods and PCR-RFLP analysis [J].
Masaoka, T ;
Suzuki, H ;
Kamiya, AG ;
Ishii, H .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2004, 20 :68-73
[9]   NUCLEOTIDE-SEQUENCE OF THE GYRA GENE AND CHARACTERIZATION OF CIPROFLOXACIN-RESISTANT MUTANTS OF HELICOBACTER-PYLORI [J].
MOORE, RA ;
BECKTHOLD, B ;
WONG, S ;
KUREISHI, A ;
BRYAN, LE .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (01) :107-111
[10]  
*NAT COMM CLIN LAB, 2004, METH DIL ANT SUSC TE
12